CTLA4 and breast carcinoma: CTLA‐4, PD‐1 and some other immune checkpoint molecules participated in the inhibiting activation of T cell by different pathways.25 The studies concerning CTLA‐4 mainly focused on breast cancer and inflammation, whereas the study on gastric cancer focused on deficiency.